Summary
This prediction ended on 19.03.18 with a price of €14.55. The BUY prediction by melinda for GSK plc closed nearly unchanged. melinda has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| GSK plc | -1.156% | -1.156% | 37.627% | 48.980% |
| iShares Core DAX® | -2.680% | 4.261% | 2.121% | 57.510% |
| iShares Nasdaq 100 | 0.725% | 5.796% | 34.204% | 92.829% |
| iShares Nikkei 225® | -0.725% | 9.319% | 61.298% | 80.340% |
| iShares S&P 500 | 1.166% | 5.479% | 24.751% | 70.967% |
According to melinda what are the pros and cons of GSK plc for the foreseeable future?
Pros
Could be worthwhile Investment >10% per year
Cons
Comments by melinda for this prediction
In the thread GlaxoSmithKline plc diskutieren
Pharmazeutische SecteurProduits Agenda 25/04 Ergebnisse Veröffentlichung
GSK stellt fest , dass ViiV Healthcare verkündet positive Daten Dolutegravir
5. März (Reuters) - Glaxosmithkline Plc :: GLAXOSMITHKLINE PLC - ViiV Healthcare KÜNDIGT NEUE DATEN ZUR BEHANDLUNG VON MENSCHEN POSITIVE Dolutegravir mit HIV-Infizierte mit TUBERCULOSIS.GLAXOSMITHKLINE CO PLC - Dolutegravir WANN 50mg zweimal täglich zu MIT NUCLEOSID DOUBLE REVERSE.